{
    "nct_id": "NCT05031780",
    "official_title": "A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease",
    "inclusion_criteria": "* Age 16 years or older (18 years or older [France and Germany]); participants age 16 or 17 years must physically have completed puberty;\n* Documented diagnosis of sickle cell disease (SCD) (HbSS, HbSC [combined heterozygosity for hemoglobins S and C], HbS/beta 0- thalassemia, HbS/ beta plus thalassemia, or other sickle cell syndrome variants);\n* At least 2 SCPCs and no more than 10 SCPCs in the past 12 months;\n* Hemoglobin at least 5.5 and 10.5 gram per deciliter (g/dL) at the most. Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by â‰¥7 days) collected during the Screening Period;\n* If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before starting study drug. Discontinuation of hydroxyurea requires a 90-day washout prior to informed assent/consent;\n* Women capable of becoming pregnant must agree to use 2 forms of contraception.\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Pregnant, breastfeeding, or parturient;\n* Receiving regularly scheduled transfusions;\n* Hepatobiliary disorders including but not limited to significant liver disease or gallbladder disease;\n* Severe kidney disease;\n* Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;\n* Currently receiving treatment with a disease-modifying therapy for SCD (eg, voxelotor, crizanlizumab, L-glutamine), with the exception of hydroxyurea. The last dose of voxelotor, crizanlizumab, and L-glutamine must have been administered at least 90 days before randomization;\n* Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered at least 90 days before starting study drug;\n* Received treatment on another investigational trial within 90 days prior to start of study drug or plans to participate in another investigational drug trial;\n* Taking medications that are strong inhibitors of CYP3A4/5 or strong inducers of CYP3A4 that cannot be stopped in an acceptable timeframe before starting study drug (timeframe will be discussed with your doctor).",
    "miscellaneous_criteria": ""
}